blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3102605

EP3102605 - COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  26.01.2024
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  12.10.2018
FormerGrant of patent is intended
Status updated on  22.05.2018
FormerExamination is in progress
Status updated on  02.06.2017
FormerRequest for examination was made
Status updated on  11.11.2016
Most recent event   Tooltip06.03.2026Change - lapse in a contracting state
State(s) deleted from list of lapses: BG		published on 08.04.2026  [2026/15]
Applicant(s)For all designated states
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 / US
For all designated states
Merck Sharp & Dohme LLC
126 East Lincoln Avenue
P.O. Box 2000
Rahway, New Jersey 07065 / US
[2023/26]
Former [2023/22]For all designated states
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 / US
For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Former [2016/50]For all designated states
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065 / US
Inventor(s)01 / MARTINI, Jean-francois, Andre
7420 Circulo Sequoia
Carlsbad, CA 92009 / US
02 / TARAZI, Jamal, Christo
10867 Pesos Place
San Diego, CA 92124 / US
03 / PERINI, Rodolfo, Fleury
707 Captains Way
Philadelphia, PA 19146 / US
04 / MAURO, David, J.
351 North Sumneytown Pike
North Wales, PA 19454 / US
 [2016/50]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2016/50]Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
Application number, filing date15703439.803.02.2015
[2016/50]
WO2015US14212
Priority number, dateUS201461935809P04.02.2014         Original published format: US 201461935809 P
[2016/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015119930
Date:13.08.2015
Language:EN
[2015/32]
Type: A1 Application with search report 
No.:EP3102605
Date:14.12.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 13.08.2015 takes the place of the publication of the European patent application.
[2016/50]
Type: B1 Patent specification 
No.:EP3102605
Date:14.11.2018
Language:EN
[2018/46]
Search report(s)International search report - published on:EP13.08.2015
ClassificationIPC:C07K16/28, A61K31/4439, A61P35/00, A61K39/395
[2016/50]
CPC:
C07K16/2818 (EP,IL,KR,US); A61K39/39558 (EP,IL,KR,US); A61K31/4439 (EP,IL,KR,US);
A61K45/06 (EP,IL,KR,US); A61P13/12 (EP,IL); A61P35/00 (EP,IL,KR);
A61P35/02 (EP,IL); A61P43/00 (EP,IL); C07K16/30 (IL,US);
C07K16/3015 (IL,US); C07K16/3023 (IL,US); C07K16/303 (IL,US);
C07K16/3038 (IL,US); C07K16/3053 (IL,US); C07K16/3061 (IL,US);
C07K16/3069 (IL,US); A61K2039/505 (KR); A61K2039/545 (KR);
A61K2300/00 (IL,KR); C07K2317/24 (IL,US); C07K2317/76 (IL,US) (-)
C-Set:
A61K31/4439, A61K2300/00 (US,EP);
A61K39/39558, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/50]
Extension statesBA10.08.2016
ME10.08.2016
TitleGerman:KOMBINATION AUS EINEM PD-1-ANTAGONISTEN UND EINEM VEGFR-INHIBITOR ZUR BEHANDLUNG VON KREBS[2016/50]
English:COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER[2016/50]
French:ASSOCIATION D'UN ANTAGONISTE DU PD-1 ET D'UN INHIBITEUR DU VEGFR POUR TRAITER LE CANCER[2016/50]
Entry into regional phase10.08.2016National basic fee paid 
10.08.2016Designation fee(s) paid 
10.08.2016Examination fee paid 
Examination procedure10.08.2016Examination requested  [2016/50]
10.08.2016Date on which the examining division has become responsible
23.03.2017Amendment by applicant (claims and/or description)
01.06.2017Despatch of a communication from the examining division (Time limit: M06)
30.11.2017Reply to a communication from the examining division
23.05.2018Communication of intention to grant the patent
28.09.2018Fee for grant paid
28.09.2018Fee for publishing/printing paid
28.09.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18205542.6  / EP3498734
EP21187795.6  / EP3971209
Opposition(s)Opponent(s)01  14.08.2019  22.08.2019  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Düsseldorf
Mönchenwerther Straße 11
40545 Düsseldorf / DE
 02  14.08.2019  22.08.2019  ADMISSIBLE
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
Opponent's representative
Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
 [N/P]
Former [2022/30]
Opponent(s)01  14.08.2019  22.08.2019  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
König Szynka Tilmann von Renesse Patentanwälte Partnerschaft mbB Düsseldorf
Mönchenwerter Straße 11
40545 Düsseldorf / DE
 02  14.08.2019  22.08.2019  ADMISSIBLE
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
Opponent's representative
Cooley (UK) LLP
22 Bishopsgate
London EC2N 4BQ / GB
Former [2021/22]
Opponent(s)01  14.08.2019  22.08.2019  ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Roth, Carla
König-Szynka-Tilmann-von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Straße 11
40545 Düsseldorf / DE
 02  14.08.2019  22.08.2019  ADMISSIBLE
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
Opponent's representative
Cooley (UK) LLP
Dashwood
69 Old Broad Street
London EC2M 1QS / GB
Former [2019/38]
Opponent(s)01  14.08.2019    ADMISSIBLE
König Szynka Tilmann von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Strasse 11
40545 Düsseldorf / DE
Opponent's representative
Roth, Carla
König-Szynka-Tilmann-von Renesse
Patentanwälte Partnerschaft mbB
Mönchenwerther Straße 11
40545 Düsseldorf / DE
 02  14.08.2019    ADMISSIBLE
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
Opponent's representative
Wilson, Justin Scott
Withers & Rogers LLP
4 More London Riverside
London SE1 2AU / GB
29.08.2019Invitation to proprietor to file observations on the notice of opposition
09.03.2020Reply of patent proprietor to notice(s) of opposition
29.07.2021Despatch of communication that the patent will be revoked
11.01.2024Legal effect of revocation of patent [2024/09]
Appeal following opposition08.10.2021Appeal received No.  T1801/21
08.10.2021Payment of appeal fee
08.12.2021Statement of grounds filed
11.01.2024Result of appeal procedure: appeal of the proprietor withdrawn
11.01.2024Date of oral proceedings
Fees paidRenewal fee
27.02.2017Renewal fee patent year 03
14.02.2018Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL14.11.2018
HR14.11.2018
LT14.11.2018
LV14.11.2018
MC14.11.2018
MK14.11.2018
RS14.11.2018
SM14.11.2018
MT03.02.2019
NO14.02.2019
IS14.03.2019
[2026/15]
Former [2022/31]AL14.11.2018
HR14.11.2018
LT14.11.2018
LV14.11.2018
MC14.11.2018
MK14.11.2018
RS14.11.2018
SM14.11.2018
MT03.02.2019
NO14.02.2019
IS14.03.2019
BG31.08.2020
Former [2021/01]AL14.11.2018
HR14.11.2018
LT14.11.2018
LV14.11.2018
MC14.11.2018
RS14.11.2018
SM14.11.2018
MT03.02.2019
NO14.02.2019
IS14.03.2019
BG31.08.2020
Former [2020/29]AL14.11.2018
HR14.11.2018
LT14.11.2018
LV14.11.2018
MC14.11.2018
RS14.11.2018
SM14.11.2018
MT03.02.2019
NO14.02.2019
IS14.03.2019
Former [2019/45]AL14.11.2018
HR14.11.2018
LT14.11.2018
LV14.11.2018
MC14.11.2018
RS14.11.2018
SM14.11.2018
NO14.02.2019
IS14.03.2019
Former [2019/37]AL14.11.2018
HR14.11.2018
LT14.11.2018
LV14.11.2018
RS14.11.2018
SM14.11.2018
NO14.02.2019
IS14.03.2019
Former [2019/26]AL14.11.2018
HR14.11.2018
LT14.11.2018
LV14.11.2018
RS14.11.2018
NO14.02.2019
IS14.03.2019
Former [2019/25]HR14.11.2018
LT14.11.2018
LV14.11.2018
RS14.11.2018
NO14.02.2019
IS14.03.2019
Former [2019/23]HR14.11.2018
LT14.11.2018
LV14.11.2018
NO14.02.2019
IS14.03.2019
Former [2019/21]LT14.11.2018
NO14.02.2019
IS14.03.2019
Former [2019/20]LT14.11.2018
NO14.02.2019
Cited inInternational search[I]   ANONYMOUS: "NCT02014636 A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Subjects With Advanced Renal Cell Carcinoma", CLINICAL TRIALS.GOV, 24 January 2014 (2014-01-24), pages 1 - 11, XP055180536, Retrieved from the Internet [retrieved on 20150331] [I] 1-20 * the whole document *
 [IY]   S. YASUDA ET AL: "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo", CLINICAL & EXPERIMENTAL IMMUNOLOGY, vol. 172, no. 3, 18 April 2013 (2013-04-18), pages 500 - 506, XP055180642, ISSN: 0009-9104, DOI: 10.1111/cei.12069 [I] 1-20 * page 501, column l, paragraph 5 * * paragraph [results] - paragraph [discussion]; figure 2 * [Y] 1-20

DOI:   http://dx.doi.org/10.1111/cei.12069
 [I]   DAVID F. MCDERMOTT ET AL: "PD-1 as a potential target in cancer therapy", CANCER MEDICINE, 21 July 2013 (2013-07-21), pages 662 - 673, XP055157252, ISSN: 2045-7634, DOI: 10.1002/cam4.106 [I] 1-20 * page 669, column r, paragraph l - page 670, column l, paragraph 2 *

DOI:   http://dx.doi.org/10.1002/cam4.106
 [Y]   BERNARD ESCUDIER ET AL: "Axitinib for the Management of Metastatic Renal Cell Carcinoma", DRUGS IN R&D, vol. 11, no. 2, 1 June 2011 (2011-06-01), pages 113 - 126, XP055180526, ISSN: 1174-5886, DOI: 10.1007/BF03259801 [Y] 1-20 * the whole document *

DOI:   http://dx.doi.org/10.1007/BF03259801
 [XP]   CLINICALTRIALS: "NCT02133742, A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer", CLINICALTRIALS.GOV ARCHIVE, 5 July 2014 (2014-07-05), XP055180147, Retrieved from the Internet [retrieved on 20150330] [XP] 1-20 * the whole document *
Examination  ATKINS: "Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results", ESMO 2016 CONGRESS, 09.10.2016,, vol. 27, no. suppl. 6, 9 October 2016 (2016-10-09) - 11 October 2016 (2016-10-11), DOI: https://doi.org/10.1093/annonc/mdw373.01 [DP]
OppositionWO2014163684
 WO2013181452
 WO2012135408
 WO2008156712
 WO2012135408
 US2004224988
   CHOUEIRI ET AL.: "Trial in progress: phase 1b dose-finding study of axitinib plus pembrolizumab for the first-line treatment of advanced renal cell carcinoma (RCC)", BJU INTERNATIONAL, vol. 114, no. S4, 21 October 2014 (2014-10-21), pages 4 - 5, XP055632141
   ANONYMOUS: "A dose finding study to evaluate safety, drug interaction, tumor markers of axitinib in combination with MK-3475 in adult patients with previously untreated advanced renal cell cancer", CLINICALTRIALS.GOV ARCHIVE, 20 June 2019 (2019-06-20), pages 1 - 9, XP055632152 * Trial in progress: Phase 1 b dose-finding study of axitinib plus pembrolizumab for first-line treatment of advanced renal cell carcinoma (RCC) The document was published in the priority interval. *
   VAN GEEL ET AL.: "Concise drug review: Pazopanib and axitinib", ONCOLOGIST, vol. 17, 25 June 2012 (2012-06-25), pages 1081 - 1089, XP055632159

DOI:   http://dx.doi.org/10.1634/theoncologist.2012-0055
   STEHLE ET AL.: "Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors", J BIOL CHEM, vol. 288, no. 23, June 2013 (2013-06-01), pages 16334 - 16347, XP055632162 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1074/jbc.M112.437962
   MCDERMOTT ET AL.: "PD-1 as a potential target in cancer therapy", CANCER MED., 21 July 2013 (2013-07-21), pages 662 - 673, XP055157252 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1002/cam4.106
   TYKODI: "Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma", vol. 5, no. 6, 3 June 2013 (2013-06-03), pages 607 - 619, XP055632192 * . The document was published before the priority date and therefore is prior art accordin to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.2217/imt.13.39
   SLIWKOWSKI ET AL.: "Antibody therapeutics in cancer", SCIENCE, vol. 341, 13 September 2013 (2013-09-13), pages 1192 - 1198, XP055079418, DOI: 10.1126/science.1241145 * . The document was published before the priority date and therefore is prior art accordin to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1126/science.1241145
   PATEL ET AL.: "Clinical cancer advances 2013: Annual report on progress against cancer from the American society of clinical oncology", J. CLIN. ONCOL., vol. 31, 10 December 2013 (2013-12-10), pages 1 - 33, XP055632195 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *
   PATNAIK ET AL.: "Phase I studv of MK -3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors", J. CLIN. ONCOL., vol. 15, 20 May 2012 (2012-05-20), pages 1, XP055632198 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *
   HAMID ET AL.: "Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma", N. ENGL. J. MED., vol. 369, no. 2, 11 July 2013 (2013-07-11), pages 134 - 144, XP055182016, DOI: 10.1056/NEJMoa1305133 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1056/NEJMoa1305133
   KAUFMAN ET AL.: "The society for immunotherapy of cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 10, 2013, pages 588 - 598, XP055632199 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1038/nrclinonc.2013.153
   BAILEY ET AL.: "Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics", THE CANCER JOURNAL, vol. 19, no. 4, July 2013 (2013-07-01), pages 348 - 352, XP055632203 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1097/PPO.0b013e31829e3153
   ANONYMOUS: "Approval label of Axitinib by the FDA", FDA, January 2012 (2012-01-01), pages 1 - 22, XP055632206 * . The document was published before the priority date and therefore is prior art accordin to Art. 54(2) EPC. *
   HU-LOWE ET AL.: "Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3", CLIN. CANCER RES., vol. 14, no. 22, 2008, pages 7272 - 7283, XP055235417, DOI: 10.1158/1078-0432.CCR-08-0652 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-08-0652
   ESCUDIER ET AL.: "Axitinib for the management of metastatic renal cell carcinoma", DRUGS IN R&D, vol. 11, no. 2, 2011, pages 113 - 126, XP055180526, DOI: 10.1007/BF03259801 * . The document was published before the priority date and therefore is prior art accordinq to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1007/BF03259801
   DORFF ET AL.: "Novel tyrosine kinase inhibitors for renal cell carcinoma", J. EXP. REV. CLIN. PHARMACOL., vol. 7, no. 1, 2 December 2013 (2013-12-02), pages 67 - 73, XP055632245 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1586/17512433.2014.862496
   DOMBLIDES ET AL.: "Emerging antiangiogenics for renal cancer", EXP. OPIN. EMERG. DRUGS, vol. 18, no. 4, 26 November 2013 (2013-11-26), pages 495 - 511, XP055632250 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1517/14728214.2013.858697
   PAL ET AL.: "Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm", MOL. CANCER THER., vol. 11, March 2012 (2012-03-01), pages 526 - 537, XP002711445, DOI: 10.1158/1535-7163.MCT-11-0806 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-11-0806
   YASUDA ET AL.: "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo", CLIN. EXP. IMMUNOL., vol. 172, no. 3, 18 April 2013 (2013-04-18), pages 500 - 506, XP055180642, DOI: 10.1111/cei.12069 * . The document was published before the priority date * * and therefore is prior art accordin to Art. 542 EPC. *

DOI:   http://dx.doi.org/10.1111/cei.12069
   TOPALIAN ET AL.: "Safety, activity, and immune correlates of anti- PD-1 antibody in cancer", N. ENG. J. MED., vol. 366, no. 26, 28 June 2012 (2012-06-28), pages 2443 - 2454, XP055098235, DOI: 10.1056/NEJMoa1200690 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1056/NEJMoa1200690
   LIPSON ET AL.: "Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody", CLIN. CANCER RES, vol. 19, no. 2, January 2013 (2013-01-01), pages 462 - 468, XP055296771, DOI: 10.1158/1078-0432.CCR-12-2625 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-12-2625
   ANONYMOUS: "WHO Drug Information", vol. 27, no. 2, 2013, pages 95, 96 - 161, 162, XP055632276 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *
   ROBERT ET AL.: "LBA - Pembrolizumab (pembro; MK -3475) for advanced melanoma: Randomized comparison of two dosing schedules", ANNALS OF ONCOLOGY, vol. 25, no. 5, 29 September 2014 (2014-09-29), pages 1, XP055632262 * (excerpt on lambrolizumab); also cited in the Opposed Patent (see p, 9, paragraph [0056]). The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *
   BAI ET AL.: "A guide to rational dosing of monoclonal antibodies.", CLIN PHARMACOKINET., vol. 51, no. 2, February 2012 (2012-02-01), pages 119 - 35, XP009184175, DOI: 10.2165/11596370-000000000-00000 * . The document was published in the priority interval. *

DOI:   http://dx.doi.org/10.2165/11596370-000000000-00000
   PARDOLL: "The blockade of immune checkpoints in cancer immunotherapy", NAT REV CANCER, vol. 12, no. 4, 22 March 2012 (2012-03-22), pages 252 - 264, XP055415943 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1038/nrc3239
   RINI ET AL.: "Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib", CLINICAL GENITOURINARY CANCER, vol. 11, no. 2, June 2013 (2013-06-01), pages 107 - 114, XP055632267 * The blockade of immune checkpoints in cancer immunotherapy. The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1016/j.clgc.2012.12.004
   ANONYMOUS: "BJU Supplements", BJU INTERNATIONAL, vol. 110, no. 2, 2012, pages 1 - 20, XP055632270 * Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib. The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *
   ANONYMOUS: "NCT2014636 A Phase I/II Study to Assess the Safety Efficacy of Pazopanib and MK -3475 in Subjects with Advanced Renal Cell Carcinoma", CLINICALSTRIALS.GOV ARCHIVE, 23 January 2014 (2014-01-23), pages 1 - 14, XP055180536
   YASUDA ET AL.: "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (Vegfr2) induces synergic anti-tumour effect in vivo", CLINICAL & EXPERIMENTAL IMMUNOLOGY, 18 April 2013 (2013-04-18), pages 1 - 7, XP055180642

DOI:   http://dx.doi.org/10.1111/cei.12069
   MCDERMOTT ET AL.: "PD-1 as a potential target in cancer therapy", CANCER MEDICINE, July 2013 (2013-07-01), pages 662 - 673, XP055157252

DOI:   http://dx.doi.org/10.1002/cam4.106
   ESCUDIER ET AL.: "Axitinib for the Management of", DRUGS IN R&D, vol. 11, no. 2, 1 June 2011 (2011-06-01), pages 113 - 126, XP055180526, DOI: 10.1007/BF03259801 * Trial in progress: Phase 1 b dose-finding study of axitinib plus pembrolizumab for first-line treatment of advanced renal cell carcinoma (RCC) The document was published in the priority interval. *

DOI:   http://dx.doi.org/10.1007/BF03259801
   ANONYMOUS: "NCT02133742, A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer", CLINICALTRIALS.GOV ARCHIVE, 12 January 2015 (2015-01-12), pages 1 - 10, XP055180147
   ESCUDIER ET AL.: "Optimal Management of Metastatic renal cell carcinoma: current status", DRUGS, vol. 73, no. 5, 10 April 2013 (2013-04-10), pages 427 - 438, XP055632312 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1007/s40265-013-0043-1
   ROBERT ET AL.: "Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies", EUR. J. CANCER., vol. 49, no. 14, 29 July 2013 (2013-07-29), pages 2968 - 2971, XP055632318 * . The document was published before the priority date and therefore is prior art according to Art. 54(2) EPC. *

DOI:   http://dx.doi.org/10.1016/j.ejca.2013.07.001
   TANG ET AL.: "Programmed Death 1 Pathway Inhibition in Metastatic Renal Cell Cancer and Prostate Cancer. Current Oncology Reports", CURR ONCOL REP., vol. 15, 22 December 2012 (2012-12-22), pages 98 - 104, XP055632325 * . The document was published before the priority date and therefore is prior art accordin to Art. 54(2) EPC. *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.